Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics

References

• EsteyEDohnerHAcute myeloid leukaemiaLancet200636895501894190717126723
   PubMed Web of Science ®Google Scholar
• TallmanMSGillilandDGRoweJMDrug therapy for acute myeloid leukemiaBlood200510641154116315870183
   PubMed Web of Science ®Google Scholar
• SchlenkRFDohnerKKrauterJMutations and treatment outcome in cytogenetically normal acute myeloid leukemiaN Engl J Med2008358181909191818450602
   PubMed Web of Science ®Google Scholar
• TraxlerPBoldGBuchdungerETyrosine kinase inhibitors: From rational design to clinical trialsMed Res Rev200121649951211607931
   PubMed Web of Science ®Google Scholar
• WahlinAMarkevarnBGolovlevaINilssonMPrognostic significance of risk group stratification in elderly patients with acute myeloid leukaemiaBr J Haematol20011151253311722406
   PubMed Web of Science ®Google Scholar
• ArbiserJLGovindarajanBBaiXFunctional tyrosine kinase inhibitor profiling: A generally applicable method points to a novel role of platelet-derived growth factor receptor-beta in tuberous sclerosisAm J Pathol2002161378178612213705
   PubMed Web of Science ®Google Scholar
• ByrdJCMrozekKDodgeRKPretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461)Blood2002100134325433612393746
   PubMed Web of Science ®Google Scholar
• PreudhommeCSagotCBoisselNFavorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: A study from the Acute Leukemia French Association (ALFA)Blood200210082717272312351377
   PubMed Web of Science ®Google Scholar
• AnderssonAJohanssonBLassenCMitelmanFBillstromRFioretosTClinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patientsEur J Haematol200472530731315059064
   PubMed Web of Science ®Google Scholar
• BullingerLDohnerKBairEUse of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemiaN Engl J Med2004350161605161615084693
   PubMed Web of Science ®Google Scholar
• DohnerKSchlenkRFHabdankMMutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutationsBlood2005106123740374616051734
   PubMed Web of Science ®Google Scholar
• StoneRMDeAngeloDJKlimekVPatients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412Blood20051051546015345597
   PubMed Web of Science ®Google Scholar
• VerhaakRGWGoudswaardCSvan PuttenWMutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): Association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significanceBlood20051063747375416109776
   PubMed Web of Science ®Google Scholar
• BullingerLDohnerKKranzRAn FLT3 gene-expression signature predicts clinical outcome in normal karyotype AMLBlood200811194490449518309032
   PubMed Web of Science ®Google Scholar
• KornblauSMTibesRQiuYHFunctional proteomic profiling of AML predicts response and survivalBlood2009113115416418840713
   PubMed Web of Science ®Google Scholar
• FielderWGraevenUErgunSExpression of FLT4 and its ligand VEGF-C in acute myeloid leukemiaLeukemia1997118123412379264375
   PubMed Web of Science ®Google Scholar
• ShawverLKSchwartzDPMannEInhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamideClin Cancer Res199737116711779815796
   PubMed Web of Science ®Google Scholar
• DiasSHattoriKHeissigBInhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemiasProc Natl Acad Sci U S A20019819108571086211553814
   PubMed Web of Science ®Google Scholar
• DiasSShmelkovSVLamGRafiiSVEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibitionBlood20029972532254011895790
   PubMed Web of Science ®Google Scholar
• MoehlerTMHillengassJGoldschmidtHHoADAntiangiogenic therapy in hematologic malignanciesCurr Pharm Des200410111221123415078137
   PubMed Web of Science ®Google Scholar
• SantosSCDiasSInternal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathwaysBlood2004103103883388914726393
   PubMed Web of Science ®Google Scholar
• KesslerTFehrmannFBiekerRBerdelWEMestersRMVascular endothelial growth factor and its receptor as drug targets in hematological malignanciesCurr Drug Targets20078225726817305503
   PubMed Web of Science ®Google Scholar
• GossageLEisenTTargeting multiple kinase pathways: A change in paradigmClin Cancer Res20101671973197820215532
   PubMed Web of Science ®Google Scholar
• StoneRMNovel therapeutic agents in acute myeloid leukemiaExp Hematol2007354 Suppl 116316617379102
   PubMed Web of Science ®Google Scholar
• FiedlerWServeHDohnerHA phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the diseaseBlood2005105398699315459012
   PubMed Web of Science ®Google Scholar
• StoverEHChenJLeeBHThe small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1 L1-PDGF Ralpha in vitro and in vivoBlood200510693206321316030188
   PubMed Web of Science ®Google Scholar
• DeAngeloDJStoneRMHeaneyMLPhase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: Safety, pharmacokinetics, and pharmacodynamicsBlood2006108123674368116902153
   PubMed Web of Science ®Google Scholar
• KnapperSBurnettAKLittlewoodTA phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapyBlood2006108103262327016857985
   PubMed Web of Science ®Google Scholar
• RobozGJGilesFJListAFPhase 1study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndromeLeukemia200620695295716617323
   PubMed Web of Science ®Google Scholar
• TongFKChowSHedleyDPharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cellsCytometry B Clin Cytom200670310711416498671
   PubMed Web of Science ®Google Scholar
• O’FarrellAMYuenHASmolichBEffects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemiaLeuk Res200428767968915158089
   PubMed Web of Science ®Google Scholar
• O’FarrellAMForanJMFiedlerWAn innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patientsClin Cancer Res20039155465547614654525
   PubMed Web of Science ®Google Scholar
• KellyLMYuJCBoultonCLCT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)Cancer Cell20021542143212124172
   PubMed Web of Science ®Google Scholar
• FiedlerWMestersRTinnefeldHA phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemiaBlood200310282763276712843001
   PubMed Web of Science ®Google Scholar
• ConsidineEBloemLBurkholderTLY2401401, a novel and orally bioavailable inhibitor of angiogenesis can be distinguished from other multi-targeted kinase inhibitors by its unique target selectivity profile and preclinical efficacyAbstr 1623. Paper presented at the 98th annual meeting of the American Association for Cancer ResearchApril 14–18, 2007Los Angeles, CA
   Google Scholar
• QuentmeierHReinhardtJZaborskiMDrexlerHGFLT3 mutations in acute myeloid leukemia cell linesLeukemia200317112012412529668
   PubMed Web of Science ®Google Scholar
• KuangSQBaiHFangZHAberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemiaBlood2010115122412241920061560
   PubMed Web of Science ®Google Scholar
• BuenoLde AlwisDPMilesCGlattSTrocónizIFSemi-mechanistic modelling of the tumour growth inhibitory effects of a new antiangiogenic drugAbstr 1474. Paper presented at: PAGE: Population Approach Group Europe meeting23–26 June, 2009St. Petersburg, Russia Abstr 1474
   Google Scholar
• BrunningRDMatutesENLHAcute Myeloid Leukaemia: Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues3Lyon, FranceIARC Press2001
   Google Scholar
• GorskiJCHuangSMPintoAThe effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivoClin Pharmacol Ther20047518910014749695
   PubMed Web of Science ®Google Scholar
• WangZGorskiJCHammanMAHuangSMLeskoLJHallSDThe effects of St John’s wort (Hypericum perforatum) on human cytochrome P450 activityClin Pharmacol Ther200170431732611673747
   PubMed Web of Science ®Google Scholar
• ZhouHTongZMcLeodJF“Cocktail” approaches and strategies in drug development: Valuable tool or flawed science?J Clin Pharmacol200444212013414747420
   PubMed Web of Science ®Google Scholar
• ZhuBOu-YangDSChenXPAssessment of cytochrome P450 activity by a five-drug cocktail approachClin Pharmacol Ther200170545546111719732
   PubMed Web of Science ®Google Scholar
• AtallahECortesJO’BrienSEstablishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemiaBlood2007110103547355117673605
   PubMed Web of Science ®Google Scholar
• ShultsKFlyeLGreenLDalyTManroJRLahnMPatient-derived acute myeloid leukemia (AML) bone marrow cells display distinct intracellular kinase phosphorylation patternsCancer Manag Res20091495921188123
   PubMedGoogle Scholar
• ChesonBDBennettJMKopeckyKJRevised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJ Clin Oncol200321244642464914673054
   PubMed Web of Science ®Google Scholar
• BelloCLMulayMHuangXElectrocardiographic characterization of the QTc interval in patients with advanced solid tumors: Pharmacokinetic-pharmacodynamic evaluation of sunitinibClin Cancer Res200915227045705219903787
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation E14 F. Guidance for Industry E14: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs Available from: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3956B3951_3902_FDA-Preliminary%3920Concept.doc. Accessed April 07, 2011.
   Google Scholar
• HallAPWestwoodFRWadsworthPFReview of the effects of antiangiogenic compounds on the epiphyseal growth plateToxicol Pathol200634213114716537292
   PubMed Web of Science ®Google Scholar
• MossKGTonerGCCherringtonJMMendelDBLairdADHair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humansJ Pharmacol Exp Ther2003307247648012966161
   PubMed Web of Science ®Google Scholar
• CreanSBoydDMSercusBLahnMSafety of multi-targeted kinase inhibitors as monotherapy treatment of cancer: A systematic review of the literatureCurr Drug Saf20094214315419442108
   PubMedGoogle Scholar
• BurkholderTPClaytonJRRempalaMEDiscovery of LY2457546: A multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft modelInvest New Drugs312011 [Epub ahead of print]
   Google Scholar
• MendelDBLairdADXinXIn vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationshipClin Cancer Res20039132733712538485
   PubMed Web of Science ®Google Scholar
• MorimotoAMTanNWestKGene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitorOncogene20042381618162614985702
   PubMed Web of Science ®Google Scholar
• StrumbergDRichlyHHilgerRAPhase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumorsJ Clin Oncol200523596597215613696
   PubMed Web of Science ®Google Scholar
• HoukBEBelloCLKangDAmanteaMA population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patientsClin Cancer Res20091572497250619258444
   PubMed Web of Science ®Google Scholar
• PengBLloydPSchranHClinical pharmacokinetics of imatinibClin Pharmacokinet200544987989416122278
   PubMed Web of Science ®Google Scholar
• Van ErpNPGelderblomHGuchelaarHJClinical pharmacokinetics of tyrosine kinase inhibitorsCancer Treat Rev200935869270619733976
   PubMed Web of Science ®Google Scholar
• CheungCGonzalezFJHumanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessmentJ Pharmacol Exp Ther2008327228829918682571
   PubMed Web of Science ®Google Scholar
• GonzalezFJCYP3A4 and pregnane X receptor humanized miceJ Biochem Mol Toxicol200721415816217936928
   PubMed Web of Science ®Google Scholar
• GonzalezFJYuAMCytochrome P450 and xenobiotic receptor humanized miceAnnu Rev Pharmacol Toxicol200646416416402898
   PubMed Web of Science ®Google Scholar
• FelmleeMALonHKGonzalezFJYuAMCytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized miceDrug Metab Dispos200836243544118048490
   PubMed Web of Science ®Google Scholar
• QuinneySKGalinskyREJiyamapa-SernaVAHydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in ratsDrug Metab Dispos20083661097110118339815
   PubMed Web of Science ®Google Scholar
• PolsterCSAtassiFWuS-JSperryDCUse of artificial stomach-duodenum model for investigation of dosing fluid effect on clinical trial variabilityMol Pharm20107515331538
   PubMed Web of Science ®Google Scholar
• CuriglianoGSpitaleriGFingertHJDrug-induced QTc interval prolongation: A proposal towards an efficient and safe anticancer drug developmentEur J Cancer200844449450018024014
   PubMed Web of Science ®Google Scholar
• CrouchMALimonLCassanoATClinical relevance and management of drug-related QT interval prolongationPharmacotherapy200323788190812885102
   PubMed Web of Science ®Google Scholar
• GojoIJiemjitATrepelJBPhase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemiasBlood200710972781279017179232
   PubMed Web of Science ®Google Scholar
• IllmerTEhningerGFLT3 kinase inhibitors in the management of acute myeloid leukemiaClin Lymphoma Myeloma20078Suppl 1S24S3418282363
   PubMedGoogle Scholar
• JenningsCDFoonKARecent advances in flow cytometry: Application to the diagnosis of hematologic malignancyBlood1997908286328929376567
   PubMed Web of Science ®Google Scholar
• BardetVTamburiniJIfrahNSingle cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometryHaematologica200691675776416769577
   PubMed Web of Science ®Google Scholar
• ChowSMindenMDHedleyDWConstitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patientsExp Hematol20063491182
   Web of Science ®Google Scholar